Clinical Trials Browser

Phase 1/2 × Axitinib × 30 days × Clear all

NCT05808608 2026-04-07

A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

Phase 1/2 Active not recruiting

Carcinoma, Renal Cell